Atilla et al. reported that dual targeting with either a CD33 CAR or a CD123 CAR and a CLL-1 CAR increased anti-tumor activity most profoundly when the target antigen expression on the tumor cells was low. This evidence concerns the gene CLEC12A and neoplasm.